REVISIÓN BIBLIOGRÁFICA: Abordaje de las convulsiones en pediatría: criterios para el tratamiento farmacológico inmediato, la vigilancia clínica y la observación hospitalaria
Authors:
- Silvia Carolina Villacres GavilanesSGSilvia Carolina Villacres Gavilanes
- Jacqueline Estefanía Alarcón HerreraJHJacqueline Estefanía Alarcón Herrera
- Lissette Alejandra Tisalema LauraLLLissette Alejandra Tisalema Laura
- Gabriela Abigail Ortega VillacresesGVGabriela Abigail Ortega Villacreses
- María Paula Villagomez MayorgaMMMaría Paula Villagomez Mayorga
Open Access
- 1 July 2026
- journal article
- Published by Center and Development of Research Projects in Salud Medicina e Innovación Journal
- Vol. 4 (3) , 372-392
Abstract
Introduction: Seizures are among the most common neurological emergencies in childhood. Accurately determining which patients require long-term antiseizure medication (ASM) therapy and which may be managed exclusively through clinical observation remains a significant clinical challenge. Objective: To analyze and standardize the clinical, electroencephalographic, and neuroimaging criteria used to distinguish pediatric patients with seizures who require pharmacological treatment from those who may be managed through observation. Methods: A systematic exploratory search was conducted in indexed databases, including PubMed, ScienceDirect, SciELO, and the Cochrane Library, using DeCS/MeSH terms. Clinical practice guidelines, meta-analyses, and clinical trials published between 2021 and 2026 were selected. Results: The available evidence indicates that a first unprovoked seizure is associated with a recurrence risk of approximately 40–50%; therefore, close clinical observation is generally the preferred management strategy. Long-term pharmacological treatment is indicated when the estimated risk of recurrence exceeds 60%, particularly in the presence of clear epileptiform discharges on electroencephalography, an abnormal baseline neurological examination, structural abnormalities on neuroimaging, or status epilepticus at presentation. Conclusion: In pediatric patients, the decision to initiate antiseizure therapy should not be determined by the dramatic clinical appearance of the first seizure. Instead, it should be based on an objective assessment of recurrence risk and a careful evaluation of the benefit–risk profile of antiseizure medications (American Academy of Pediatrics, 2022; Berg et al., 2022; National Institute for Health and Care Excellence, 2022).Keywords
This publication has 7 references indexed in Scilit:
- Fenfluramine treatment for Dravet syndrome: Long term real‐world analysis demonstrates safety and reduced health care burdenEpilepsia, 2024
- Factors Affecting the Perception of Strabismus Among Pediatric OphthalmologistsJournal of Pediatric Ophthalmology & Strabismus, 2023
- Evidence Base for 2022 Updated Recommendations for a Safe Infant Sleeping Environment to Reduce the Risk of Sleep-Related Infant DeathsPediatrics, 2022
- Qualitative health research in the fields of developmental medicine and child neurologyDevelopmental Medicine & Child Neurology, 2022
- Mutations associated with epileptic encephalopathy modify EAAT2 anion channel functionEpilepsia, 2021
- The efficacy and safety of adjunctive perampanel for the treatment of refractory focal‐onset seizures in patients with epilepsy: A meta‐analysisEpilepsia Open, 2021
- Screening of prototype antiseizure and anti‐inflammatory compounds in the Theiler's murine encephalomyelitis virus model of epilepsyEpilepsia Open, 2021